Reduction of renal triglyceride accumulation: effects on proximal tubule Na\(^+\)/H\(^+\) exchange and urinary acidification

I. Alexandru Bobulescu, Michele Dubree, Jianning Zhang, Paul McLeroy, and Orson W. Moe

Departments of Internal Medicine and Physiology and Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, Texas

Submitted 30 March 2009; accepted in final form 14 August 2009

Bobulescu IA, Dubree M, Zhang J, McLeroy P, Moe OW. Reduction of renal triglyceride accumulation: effects on proximal tubule Na\(^+\)/H\(^+\) exchange and urinary acidification. Am J Physiol Renal Physiol 297: F1419–F1426, 2009. First published August 19, 2009; doi:10.1152/ajprenal.00177.2009.—One main pathophysiological mechanism underlying the increased risk for uric acid nephrolithiasis in humans with the metabolic syndrome is the excretion of unduly acidic urine, in part because of reduced excretion of the main urinary buffer, ammonium. The Zucker diabetic fatty (ZDF) rat, an established rodent model of the metabolic syndrome, has similar urinary abnormalities, attributed in part to lower expression and functional abnormalities induced by fat loading in a cell culture model of proximal tubule steatosis and lipotoxicity. These defects are associated with renal tubular steatosis in ZDF rats, but the causal relationship between renal steatosis and defective urinary acidification has not been investigated in vivo. We hypothesized that reduction of renal steatosis would commensurately normalize urinary acidification parameters. We treated ZDF rats with thiazolidinediones to reduce nonadipose tissue steatosis. Four weeks of treatment reduced renal triglyceride accumulation and restored urinary acidification parameters in ZDF rats to levels comparable to their lean littermates; urinary acidification was not affected by treatment in lean rats. To further document the direct effects of fat, we showed that functional abnormalities induced by fat loading in a cell culture model of proximal tubule steatosis and lipotoxicity can be reversed by fat removal but not by thiazolidinediones alone. Together, these findings support the causative role of renal steatosis in the pathogenesis of urinary acidification defects, demonstrate reversibility upon lipid removal, and highlight a potential therapeutic strategy for renal abnormalities in the metabolic syndrome.

\(\text{Na}^+\)/\(\text{H}^+\) exchanger 3; metabolic syndrome; renal lipotoxicity; ammonium; uric acid nephrolithiasis

Humans with features of the metabolic syndrome excrete an overly acidic urine and, as a consequence, have an increased propensity for uric acid nephrolithiasis (9, 16, 27, 36, 42, 45). Low urine pH in these patients has been attributed in part to decreased excretion of the principal urinary buffer, ammonium (\(\text{NH}_4^+\)) (9, 18, 21, 37, 42), but the pathophysiology underlying this defect is unknown.

\(\text{NH}_4^+\) excreted in the urine originates principally from the mitochondrial metabolism of glutamine to glutamate and then to \(\alpha\)-ketoglutarate, releasing ammonia (\(\text{NH}_3\)) in the proximal tubule cell (35). Intracellularly produced \(\text{NH}_3\) can either diffuse across the brush border and be trapped in the tubular lumen by protonation to \(\text{NH}_4^+\) or be protonated in the cell and cross the lipid bilayer as \(\text{NH}_3\). \(\text{Na}^+\)/\(\text{H}^+\) exchanger 3 (NHE3) is important for both transport processes by extruding the \(\text{H}^+\) necessary for luminal trapping of \(\text{NH}_3\), and by functioning as a \(\text{Na}^+\)/\(\text{NH}_4^+\) exchanger (24, 33–35). Downstream of the proximal tubule, \(\text{NH}_3/\text{NH}_4^+\) is in part retrieved in the thick ascending limb of Henle’s loop, concentrated in the renal medulla, and resorbed in the collecting duct, while some is returned to the systemic circulation (35). Decreased \(\text{NH}_4^+\) excretion in the urine can result from insufficient production, defective extrusion into the proximal tubule lumen, or downstream transport defects resulting in reduced net renal excretion.

One abnormality associated with organ dysfunction in the metabolic syndrome is the disrupted balance of nonadipose tissue lipid uptake, synthesis, and utilization, leading to intracellular accumulation of free nonesterified fatty acids (FFA), triglycerides, and lipid metabolites, a phenomenon generally referred to as steatosis (43, 48, 54). Cellular lipid overload may result in dysfunction and injury in nonadipose tissues, a process that has been termed lipotoxicity and has been linked to organ dysfunction in the heart, skeletal muscle, liver, and pancreatic \(\beta\)-cell (43, 48, 50, 54). Lipotoxicity may also occur in the kidney, but its effects on renal function are incompletely understood (2, 51, 54). The proximal tubule may be particularly susceptible to lipotoxicity, because of its critical role in retrieving the FFA-bearing albumin normally filtered at the glomerulus (5, 20, 41, 54). Elevated FFA levels in the metabolic syndrome (39, 49) result in a higher FFA-to-albumin molar ratio and may expose the proximal tubule to an increased load of FFA from both the interstitium and the tubule lumen (5, 54).

Zucker diabetic fatty (ZDF) rats, an established model of obesity and metabolic syndrome (10), have a urinary biochemical profile highly similar to that of humans with the metabolic syndrome, including impaired \(\text{NH}_4^+\) excretion, low urine pH, and high titratable acidity (TA) (6). These abnormalities have been attributed in part to reduced proximal tubule brush-border NHE3 expression and activity and are associated with increased circulating FFA and renal proximal tubule steatosis (6). Incubation of proximal tubule-like opossum kidney (OKP) cells (12) with a mixture of FFA carried on albumin resulted in intracellular triglyceride accumulation, impaired NHE3 activity and regulation, and reduced \(\text{NH}_4^+\) production, supporting a causal link between proximal tubule lipotoxicity and defective urinary acidification (6).

One important question regarding the functional abnormalities associated with proximal tubule lipotoxicity is whether reducing fat accumulation can restore or preserve normal function. This question not only bears relevance to the pathophysiology of renal lipotoxicity but may also have clinical therapeutic implications. We tested this, using the ZDF rat model as well as a proximal tubule cell culture model. We
examined renal lipid accumulation, urinary biochemistry, and proximal tubular brush-border NHE3 in ZDF rats treated with two members of the thiazolidinedione (TZD) family of peroxisome proliferator-activated receptor-\(\gamma\) (PPAR\(\gamma\)) agonists. These drugs have been shown to reduce skeletal muscle, heart, and liver steatosis in humans and animal models (4, 22, 38, 47, 52, 57), primarily by redistributing lipids to the adipose tissue (44, 55). The direct effects of intracellular lipid reduction and TZD treatment were also examined in lipid-loaded OKP cells, a cell culture model of proximal tubule lipotoxicity (6).

**EXPERIMENTAL PROCEDURES**

**Materials and supplies.** All chemicals were purchased from Sigma-Aldrich (St. Louis, MO), except where otherwise noted, and except for the following: cell culture media, 2,7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein, acetoxymethyl ester (BCECF-AM), and immunopure immobilized streptavidin (Pierce, Rockford, IL); protease inhibitor cocktail tablets (Roche Applied Science, Indianapolis, IN); horseradish peroxidase-labeled anti-mouse IgG and enhanced chemiluminescence detection kit (Amersham Biosciences, Piscataway, NJ); polyvinylidene difluoride membranes (Immobilon, Millipore, Billerica, MA).

**Animals.** The study protocol was approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Texas Southwestern Medical Center. Experiments were conducted in accordance with institutional guidelines and with the Guide for the Care and Use of Laboratory Animals (National Academy Press, 1996). Thirty-two male 8-wk-old ZDF (fa/fa) rats and their lean wild-type (+/+) littermates were a generous gift from Dr. Roger Unger (University of Texas Southwestern Touchstone Center for Diabetes Research). Animals were fed standard rodent diets (Harlan Teklad, Madison, WI) with or without troglitazone (Sankyo, Tokyo, Japan; 400 mg/kg chow) or rosiglitazone (GlaxoSmithKline, Brentford, UK; 40 mg/kg chow) for 4 wk. The effects of troglitazone and rosiglitazone on renal acidification and lipid parameters were indistinguishable, and therefore the results are reported collectively. For urine collections, rats were pair fed standard chow in metabolic cages and ready to the same amount of total protein were heated for 2 min at 95°C in isolation buffer containing fresh protease inhibitors, and crude membranes were obtained by centrifugation at 48,000 g for 1 h at 2°C (Beckman J2–21M; JA-20 rotor; Beckman Coulter, Fullerton, CA)._pellets were resuspended, homogenized in a Dounce glass homogenizer, and subjected to Mg\(^{2+}\) aggregation by addition of MgCl\(_2\) to a final concentration of 15 mM at 4°C for 20 min. Aggregated membranes were removed by centrifugation at 3,000 g for 10 min at 2°C (Beckman Allegra 21R; Beckman Coulter), and the supernatant was subjected to two additional rounds of Mg\(^{2+}\) aggregation as above (pellets discarded), followed by centrifugation at 48,000 g for 30 min at 2°C. The resulting pellet enriched in BBMV was used for Na\(^+/\)H\(^+\) exchange activity experiments and for immunoblotting.

For Na\(^+/\)H\(^+\) exchange activity in BBMV, Na\(^+/\)H\(^+\) exchange activity was measured in fresh BBMV with the acridine orange fluorescence quenching method (53) as previously described (6). Briefly, the BBMV pellet obtained as above was rehomogenized in intravesicular solution [280 mM mannitol, 5 mM 2-(N-morpholino)ethanesulfonic acid (MES), pH 5.5] with a Potter-Elvehjem Teflon-glass homogenizer, equilibrated for 2 h at 4°C, centrifuged at 48,000 g, and resuspended at a final protein concentration of 15 mg/ml. Tissue triglycerides were measured by stripping and reprobing with a monoclonal anti-NHE3 antigen in BBMV.

**Rat kidney cortex BBMV prepared as above were homogenized in RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 5 mM EDTA, 1% Triton X-100, 0.5% deoxycholate, and 0.1% SDS) containing fresh protease inhibitors and cleared by centrifugation (14,000 g, 4°C, 30 min), and protein content was determined by the method of Bradford. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting were performed as described previously (7). Briefly, samples containing the same amount of total protein were heated for 2 min at 95°C in loading buffer, size fractionated by SDS-PAGE, and transferred to polyvinylidene difluoride membranes with a Trans-Blot SD semidry electrophoretic transfer cell (Bio-Rad, Hercules, CA). Membranes were blocked in nonfat milk, probed overnight at 4°C with the 3H3 monoclonal anti-NHE3 antibody at 1:1,000 dilution (7), washed (5 × 10 min, 0.05% Tween 20 in PBS), incubated with a horseradish peroxidase-labeled secondary antibody for 1 h, washed as above, and visualized by enhanced chemiluminescence. Equivalent loading was confirmed by stripping and reprobing with a monoclonal anti-\(\beta\)-actin antibody prepared at the same time from rats killed on the same day. Quantification of protein abundance was performed with Scion/NIH Image software (Scion, Frederick, MD).

**Preparation of BBMV.** Renal cortical BBMV were prepared by the Mg\(^{2+}\) aggregation method as previously described (6). Briefly, fresh kidney cortical samples were homogenized as above in ice-cold solution buffer containing fresh protease inhibitors, and crude membranes were obtained by centrifugation at 48,000 g for 1 h at 2°C (Beckman J2–21M; JA-20 rotor; Beckman Coulter, Fullerton, CA). Pellets were resuspended, homogenized in a Dounce glass homogenizer, and subjected to Mg\(^{2+}\) aggregation by addition of MgCl\(_2\) to a final concentration of 15 mM at 4°C for 20 min. Aggregated membranes were removed by centrifugation at 3,000 g for 10 min at 2°C (Beckman Allegra 21R; Beckman Coulter), and the supernatant was subjected to two additional rounds of Mg\(^{2+}\) aggregation as above (pellets discarded), followed by centrifugation at 48,000 g for 30 min at 2°C. The resulting pellet enriched in BBMV was used for Na\(^+/\)H\(^+\) exchange activity experiments and for immunoblotting.

**Na\(^+/\)H\(^+\) exchange activity in BBMV, Na\(^+/\)H\(^+\) exchange activity was measured in fresh BBMV with the acridine orange fluorescence quenching method (53) as previously described (6). Briefly, the BBMV pellet obtained as above was rehomogenized in intravesicular solution [280 mM mannitol, 5 mM 2-(N-morpholino)ethanesulfonic acid (MES), pH 5.5] with a Potter-Elvehjem Teflon-glass homogenizer, equilibrated for 2 h at 4°C, centrifuged at 48,000 g, and resuspended at a final protein concentration of 15 mg/ml. Tissue triglycerides were measured by stripping and reprobing with a monoclonal anti-NHE3 antigen in BBMV.
serum-free low-glucose (100 mg/dl) DMEM-containing vehicle (albumin) for a total of 72 h, as follows: to study lipotoxicity, FFA were added to the cells during the last 12 h of serum deprivation; to study lipotoxicity reversal, cells were serum deprived for 24 h and then FFA were added for 12 h, followed by 36 h of incubation in FFA-free medium before experiments. Before assays, cells were incubated with or without insulin (10^{-5} M) for 2 h. For osmolitazone treatment, confluent OKP cells were incubated with 0.75 mM FFA carried on albumin or albumin alone for 24 h in serum-free medium supplemented with 25 mM N-2-hydroxyethylpiperazine-N‘-2-ethanesulfonic acid (HEPES, pH 7.4), with addition of either vehicle (dimethyl sulfoxide) or excipient-free osmolitazone (Cayman Chemical, Ann Arbor, MI) at the indicated concentrations.

**Apical membrane NHE3 antigen in OKP cells.** Confluent OKP cells were rinsed with ice-cold isotonic wash buffer (in mM: 137 NaCl, 2.7 KCl, 10 Na₂HPO₄, 2 KH₂PO₄, 1 MgCl₂, 0.1 CaCl₂, pH 7.4) and incubated with 3 ml of biotinylation buffer (1.5 mg/ml sulfo-NHS-SS-Biotin, 2 mM CaCl₂, 150 mM NaCl, 10 mM triethanolamine, pH 7.4) for 90 min with horizontal motion at 4°C. After biotin labeling, cells were washed twice with 6 ml of quenching buffer (in mM: 1 MgCl₂, 0.1 CaCl₂, 100 glycine in PBS, pH 7.4, for 20 min at 4°C) and lysed in RIPA buffer with protease inhibitors as previously described (7). Lysates were cleared by centrifugation (14,000 rpm, 20 min, 4°C) and diluted to 400 μg/ml protein and equilibrated overnight at 4°C with streptavidin-beads on an end-over-end rotator. Beads were washed three times with 2 ml of wash buffer (50 mM Tris·HCl, pH 7.4, 100 mM NaCl, 5 mM EDTA), two times with solution B (in mM: 50 Tris·HCl, pH 7.4, 500 NaCl), and once with solution C (50 mM Tris·HCl, pH 7.4), each time with recovery by centrifugation at 1,000 g for 1 min. Beads were then heated to 95°C in 2.5× loading buffer, and the supernatant was subjected to SDS-PAGE and immunoblotting as above.

**Apical Na⁻/H⁺ exchange activity in OKP cells.** Intracellular pH (pHᵢ) was monitored with a computer-controlled spectrofluorometer (λ excitation: 500 and 450 nm, λ emission: 530 nm) in cells grown on glass coverslips and loaded with the intracellularly trapped pH-sensitive dye BCECF as described previously (7, 32). Calibration of the 500-to-450 nm fluorescence ratio to pHᵢ was performed with the nigericin-induced acid load, in the absence of CO₂/HCO₃⁻ diffusion (Fig. 2, A–C). Of note, urinary citrate was lower in ZDF rats compared with their lean littermates, and this difference was also reversed by TZD treatment (Fig. 2D). These differences could not be attributed to acid-base disturbances or differential acid or alkali intestinal absorption, since acid-base status and urinary sulfate and potassium excretion were not different between the groups (Table 1).

**RESULTS**

**Effect of TZD on plasma and renal lipid abnormalities in ZDF rats.** Compared with their lean littermates, ZDF rats have higher levels of FFA in the plasma and accumulate excess triglycerides in the renal cortex (6). Treatment of ZDF rats with PPARγ agonists has been shown to reduce plasma FFA (13, 52) and lipid accumulation in the heart, skeletal muscle, and liver (22, 52), but the effect on kidney triglyceride accumulation has not been studied. ZDF rats treated with TZD for 4 wk gained more weight than untreated ZDF rats, but their average decapsulated kidney weight was not different (Table 1). Treatment with TZD significantly decreased plasma FFA levels and renal cortical triglyceride content in ZDF rats, while having no detectable effect in their lean littermates (Fig. 1).

**Effect of TZD on urinary acidification parameters in ZDF rats.** We showed previously (6) that high circulating FFA and renal triglyceride accumulation in ZDF rats are associated with urinary acidification defects, primarily due to inappropriate NH₄⁺ excretion. The causal relationship between lipid abnormalities and defective NH₄⁺ production and/or transport has been tested in vitro in cell culture but not in vivo (6). We examined causality in vivo by reducing plasma FFA and the development of renal steatosis in ZDF rats with TZD treatment. The amelioration of lipid abnormalities in TZD-treated ZDF rats was accompanied by changes in urinary acidification parameters including urinary pH, NH₄⁺, and TA to values close to those in lean rats, while TZD treatment in lean rats, in the absence of lipid abnormalities, had no effect on urinary acidification (Fig. 2, A–C). Of note, urinary citrate was lower in ZDF rats compared with their lean littermates, and this difference was also reversed by TZD treatment (Fig. 2D). These differences could not be attributed to acid-base disturbances or differential acid or alkali intestinal absorption, since acid-base status and urinary sulfate and potassium excretion were not different between the groups (Table 1).

**Table 1. Plasma and urinary parameters in ZDF rats with or without TZD treatment**

<table>
<thead>
<tr>
<th></th>
<th>Lean</th>
<th>Lean + TZD</th>
<th>ZDF</th>
<th>ZDF + TZD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Body and kidney weights</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body wt, g</td>
<td>288±15</td>
<td>294±19</td>
<td>395±13*</td>
<td>456±28†‡</td>
</tr>
<tr>
<td>Kidney wt, g</td>
<td>1.19±0.07</td>
<td>1.21±0.09</td>
<td>1.51±0.15*</td>
<td>1.56±0.19†</td>
</tr>
<tr>
<td>Kidney/body wt, %</td>
<td>0.414±0.038</td>
<td>0.413±0.047</td>
<td>0.382±0.046*</td>
<td>0.342±0.054*</td>
</tr>
<tr>
<td><strong>Blood chemistry</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>7.38±0.01</td>
<td>7.38±0.02</td>
<td>7.38±0.02</td>
<td>7.37±0.03</td>
</tr>
<tr>
<td>Na⁺, meq/l</td>
<td>141.5±2.22</td>
<td>142.5±2.35</td>
<td>139.63±2.43</td>
<td>140.5±3.87</td>
</tr>
<tr>
<td>K⁺, meq/l</td>
<td>4.68±0.62</td>
<td>4.73±0.48</td>
<td>5.58±1.49</td>
<td>5.48±1.45</td>
</tr>
<tr>
<td>Cl⁻, meq/l</td>
<td>105.17±1.47</td>
<td>104.33±1.97</td>
<td>102±3.27</td>
<td>101.88±4.25</td>
</tr>
<tr>
<td>HCO₃⁻, meq/l</td>
<td>24.50±2.43</td>
<td>24.33±2.66</td>
<td>25.38±1.65</td>
<td>25.63±1.25</td>
</tr>
<tr>
<td>Anion gap, meq/l</td>
<td>16.52±1.52</td>
<td>18.57±3.40</td>
<td>17.83±2.67</td>
<td>18.48±3.35</td>
</tr>
<tr>
<td><strong>Urinary markers of acid-base intake</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SO₄²⁻/creatinine, μmol/mg</td>
<td>29.43±5.31</td>
<td>29.04±4.3</td>
<td>29.55±4.87</td>
<td>28.88±4.63</td>
</tr>
<tr>
<td>SO₄²⁻, μmol/24 h</td>
<td>206.37±37.44</td>
<td>212.6±31.45</td>
<td>233.75±38.56</td>
<td>220.4±35.32</td>
</tr>
<tr>
<td>K⁺/creatinine, meq/mg</td>
<td>0.193±0.045</td>
<td>0.202±0.07</td>
<td>0.208±0.058</td>
<td>0.2±0.05</td>
</tr>
<tr>
<td>K⁺, meq/24 h</td>
<td>1.36±0.32</td>
<td>1.48±0.51</td>
<td>1.65±0.46</td>
<td>1.53±0.38</td>
</tr>
</tbody>
</table>

Values are means ± SD. ZDF, Zucker diabetic fatty; TZD, thiazolidinedione. *P < 0.01 vs. untreated lean rats; †P < 0.01 vs. TZD-treated lean rats; ‡P < 0.01 vs. untreated ZDF rats (n = 15 or 16).

**Statistics.** Statistical analysis was performed with Student’s t-test and ANOVA as specified in Figs. 1–5. Results are presented graphically as means and SD. For animal experiments, n = 8 per condition unless otherwise noted.
NHE3 antigen and activity in ZDF rats treated with TZD.

The Na⁺/H⁺ exchanger NHE3 is critical for NH₄⁺ transport in the proximal tubule (24, 33–35), and reduced expression and activity of NHE3 at the proximal tubule brush-border membrane may account at least in part for the decreased urinary NH₄⁺ and pH in ZDF rats (6). We next tested whether the amelioration of lipid abnormalities and urinary acidification defects in ZDF rats treated with TZD is accompanied by a corresponding increase in proximal tubule NHE3 expression and function. Rosiglitazone treatment was previously shown to have no effect on renal cortical NHE3 protein in ZDF rats (40), but this finding does not distinguish between brush-border NHE3, which participates in luminal transport, and intracellular NHE3. In addition, NHE3 activity can change without commensurate changes in protein abundance (8, 31). To determine the effect of TZD on NHE3 function at the lumen of the proximal tubule, we measured NHE3 antigen and Na⁺/H⁺ exchange activity in isolated proximal tubule BBMV. TZD treatment was accompanied by a significant increase in brush-border NHE3 protein abundance and activity in ZDF rats, while having no detectable effect in lean rats (Fig. 3).

Reversibility of lipotoxic effects in OKP cells incubated with fatty acids. ZDF rats have a constellation of metabolic abnormalities, and TZD treatment may improve renal acidification and NHE3 function by acting on mechanisms independent of renal lipid content. We used FFA-incubated OKP cells to investigate the effect of intracellular lipid reduction in the absence of other potential confounding factors. OKP cells avidly take up FFA carried on albumin from the culture medium and store them predominantly as triglycerides in intracellular lipid droplets (46). OKP cells also appear to be rather susceptible to lipotoxicity. While a high dose of FFA (1.5 mM) causes irreversible cellular damage by promoting apoptosis, a low dose of FFA (0.75 mM), with no significant effect on apoptosis or baseline NHE3 activity, is sufficient to abolish the insulin stimulation of NHE3 function (6). We examined the reversibility of this phenomenon in lipid-loaded OKP cells maintained in a nutrient-poor medium to promote lipid catabolism, mitochondrial beta-oxidation of intracellular FFA, and hence recovery from lipotoxicity. Compared with cells studied immediately after lipid loading (Fig. 4A), intracellular lipid droplets were markedly reduced in cells allowed to recover for 36 h (Fig. 4B) and the regulation of NHE3 by insulin was partly restored (Fig. 4C). Cells maintained in nutrient-poor medium continued to reduce their intracellular lipid stores and remained viable in culture for up to 6 days, but NHE3 activity and insulin response gradually decreased with prolonged serum and nutrient deprivation in both vehicle- and FFA-incubated cells (not shown). These cell culture artifacts...
seen with prolonged serum starvation make these later time points unsuitable for the study of NHE3 regulation.

Effect of rosiglitazone on NHE3 activity in OKP cells. Our findings in lean control rats do not support a direct effect of TZD on urinary acidification in the absence of renal steatosis (Fig. 2). However, the presence of intracellular lipid deposits may alter the transcriptional and metabolic makeup of the proximal tubule, and it is theoretically possible that TZD may have a direct effect on urinary acidification in the altered environment of the steatotic kidney. This effect, if present, would not be related to the reduction of steatosis but rather to TZD, which would drastically alter the interpretation of our data. To examine this possibility, we incubated control and lipid-loaded OKP cells with different concentrations of rosiglitazone for 24 h. Rosiglitazone treatment had no effect on intracellular lipid content in OKP cells, as estimated by Oil Red O staining (not shown). Incubation of OKP cells with either 1 μM or 10 μM rosiglitazone had no effect on apical Na+/H+ activity (Fig. 5).

DISCUSSION

One renal manifestation of the metabolic syndrome in both humans and ZDF rats is an excessively acidic urine, attributed in part to impaired urinary NH4+ excretion (6, 9, 16, 27, 28). Decreased NHE3 expression and activity in the proximal tubule brush border contribute to this defect in ZDF rats, although other factors such as decreased glutamine metabolism due to mitochondrial substrate competition by excess intracellular FFA could also play a role (6). Impaired luminal acid extrusion via NHE3 could also explain the reduced excretion of urinary citrate in ZDF rats, since intracellular acidification in the proximal tubule upregulates both citrate reabsorption and citrate metabolism (1, 29). Hypocitraturia in these animals cannot be attributed to differences in acid or alkali intestinal absorption, given that urinary sulfate and potassium were not different in ZDF and lean rats. These functional abnormalities are accompanied by renal steatosis with predominant tubular localization in ZDF rats and can be reproduced in part in a cell culture model of proximal tubule lipotoxicity, OKP cells incubated with FFA (6). Renal steatosis and lipotoxicity may thus be an important factor in the pathophysiology of renal acidification defects associated with the metabolic syndrome.
We have shown that TZD treatment in ZDF rats reduces renal steatosis. The antisteatotic action of TZD has been described in humans and animal models of the metabolic syndrome in the liver, heart, and skeletal muscle (4, 22, 38, 47, 52, 57), but to our knowledge the effect of TZD on renal triglyceride content has not been previously examined. Reduction of renal fat with TZD in ZDF rats was accompanied by a shift in urinary NH$_4^+$ concentration, pH, TA, and citrate to levels comparable with lean control rats, in the absence of renal steatosis. The concurrent reduction in renal triglycerides and normalization of NHE3 and urinary parameters strongly suggest correction of functional abnormalities with renal lipid mobilization, and thus support the causal relationship between renal steatosis and urinary acidification defects in vivo.

The effect of TZD on renal steatosis and functional abnormalities is likely attributable to PPAR$\gamma$ activation in the adipose tissue, which in turn decreases nonadipose tissue lipotoxicity by redistributing lipids to adipocytes (44, 55). However, in a whole animal model like the ZDF rat there are always possible confounding factors that may account for our observations.

First, even though the lack of effect of TZD on urinary parameters in lean rats argues against a direct effect of TZD on proximal tubule acidification, the possibility remains that a direct effect of PPAR$\gamma$ agonism is only evident in the background of lipid-laden proximal tubule cells. We tested this directly by incubating control and lipid-loaded OKP cells with rosiglitazone and examining NHE3 as a surrogate readout. There was no effect of rosiglitazone on NHE3 activity until we reached 100 $\mu$M, a concentration two orders of magnitude higher than the maximum concentration of free (non-protein bound) drug (26). High concentrations of rosiglitazone in cell culture induce intracellular acidosis and may thus increase Na$^+$/H$^+$ exchange indirectly (11). Importantly, the effect of rosiglitazone was not different in control and lipid-loaded cells. On the basis of our findings in rats and OKP cells, it is unlikely that therapeutic doses of rosiglitazone exert a direct effect on proximal tubule Na$^+$/H$^+$ or Na$^+$/NH$_4^+$ exchange in vivo.

Second, it is possible that the reduction of renal steatosis and the urinary acidification changes in ZDF rats treated with TZD are merely parallel phenomena, not linked by a causal relationship but rather resulting from common upstream effects of PPAR$\gamma$ agonism. Furthermore, mobilization of triglyceride deposits may actually increase the renal lipotoxic burden, since the breakdown of triglycerides could increase the intracellular availability of their downstream toxic metabolites (25, 43, 54). We tested this by reducing intracellular lipid accumulation in lipid-loaded OKP cells, which restored the impaired insulin-regulated NHE3 activity associated with proximal tubule lipotoxicity (6).

The mechanisms by which renal steatosis affects proximal tubule Na$^+$/H$^+$ exchange in vivo are complex and incompletely understood. On the basis of this and our previous work (6), it appears that severe lipid loading may lead to tubular damage, increased apoptosis, and a relatively unspecific impairment of proximal tubular function, while moderate lipid loading may have more restricted and specific effects by impairing the normal regulation of NHE3 by certain agonists such as insulin and glucocorticoids. In apparent contrast to the in vivo situation, moderate lipid loading in vitro in OKP cells does not affect baseline NHE3 activity, because these physiological NHE3 agonists are absent from regular cell culture media.

Of note, while impaired NH$_4^+$ excretion and reduced Na$^+$/H$^+$ activity in ZDF rats are both reversed by TZD treatment, it is highly unlikely that NHE3 is the sole determinant of differences in urinary NH$_4^+$ in these animals. The quantitative discrepancy between brush-border membrane Na$^+$/H$^+$ exchange and NH$_4^+$ excretion in ZDF rats is compatible with a multihit model, in which other factors such as mitochondrial NH$_4^+$ production and/or NH$_4^+$ transport downstream of the proximal tubule may contribute to the overall urinary NH$_4^+$ excretion defect. These factors are also corrected by TZD treatment in ZDF rats, via mechanisms that require further studies.

Together, our experiments in rodents and in cultured cells support the hypothesis that renal steatosis may be one of the factors responsible for unduly acidic urine in the metabolic syndrome. In addition, our findings raise the possibility that treatment with PPAR$\gamma$ agonists could reduce renal fat accumulation, having as one consequence improved urinary acidification and, in humans, decreased risk for uric acid stone formation.

Renal steatosis and the antisteatotic action of TZD in the kidney are likely to have multiple effects beyond urinary acidification. Several lines of evidence in both humans and animal models have associated TZD treatment with surrogate markers of renal protection in type 2 diabetes and the metabolic syndrome (3, 23, 30, 56), but whether this effect is at least in

**Fig. 5. Effect of rosiglitazone on NHE3 activity in OKP cells.** Apical Na$^+$/H$^+$ exchange activity was measured in confluent quiescent OKP cells incubated with vehicle (albumin) or 0.75 mM FFA for 24 h, with addition of rosiglitazone at the indicated concentrations. *$P < 0.01$ by 1-way ANOVA ($n = 6$/group).
part due to decreased steatosis in the kidney requires further exploration.

Importantly, whether humans accumulate fat in the kidney and whether renal steatosis causes damage in a similar fashion are currently unknown. A comprehensive approach to renal steatosis is required to establish its importance in human pathophysiology, including experiments aimed to characterize its correlation with systemic disease and its effects on various aspects of renal function, including but not limited to urinary acidification.

ACKNOWLEDGMENTS

The authors are grateful to Dr. Roger Unger for expert advice and for generously providing ZDF rats and to Janice Koska, Kathy Rodgers, Alan Stewart, and Anthony Nguyen for technical assistance.

GRANTS

This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants P01-DK-020543, R01-DK-48482 and R01-DK-081423 and by a grant from the Simmons Family Foundation (to O. W. Moe). These studies utilized the Biomedical Cores of the O’Brien Kidney Center (P30-DK-079328). I. A. Bobulescu was supported by a Fellowship Grant from the National Kidney Foundation, by a Seed Grant from the Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, and by the Carl W. Gottschalk Research Scholar Award from the American Society of Nephrology.

REFERENCES


